EN DE
Watch Trevi Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Trevi Therapeutics Inc (TRVI) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Trevi Therapeutics Inc stock $9.79, price $14.91, that is 34.3% below the price, quality 35 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

TT Trevi Therapeutics Inc logo Thin data Nov 11, 2026

Trevi Therapeutics Inc

TRVI · US
Expensive, weak quality

Our calculation puts a fair price 34% below what the stock costs today.

Low debt
Mixed vs. peers (4/8)
Insiders sold $595,806 (6M)
Fair value $9.79 · Overvalued
Quality 35/100
Negative free cash flow
Narrow moat 5/100 · thin data
Thin data
Estimate
Watch Trevi Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$19.50 $0.4600 Fair Value $9.79 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $0.4600 – $19.50 · fair‑value band $7.34 – $12.23 · the $14.91 price screens above the $9.79 fair value. As of Nov 11, 2026.

Follow Trevi Therapeutics in your weekly email

Every Wednesday you see whether Trevi Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.

Show moreShow less

The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.

Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Stock analysis

Trevi Therapeutics Inc (TRVI) currently trades at $14.91, while our estimate is $9.79, 34% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $7.34 (bear) to $12.23 (bull), the price of $14.91 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Trevi Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$42.8M in FY2025.

Key figures

Market cap $2.3B Mid · EPS (TTM) $−0.3700 · Return on equity −19.7% · Return on assets (EBIT) −43.7% (5-year average) · Free cash flow −$42.1M · Net cash $18.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 24% below its 52-week high and 49% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −34%, TRVI screens richer than that median.

Fair Value

Bear $7.34 Fair Value $9.79 Bull $12.23
Price $14.91 · Downside -34.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 32
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 11
Does it invest with discipline instead of growing at any price?
Low Volatility 28
How calm the share price moves, does not count
Price momentum 42
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 62
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $595,806 and none bought.

  • SaleMichael Thomas HeffernanDirector39,473 shares at $15.09$595,806Sep 15, 202610b5-1 plan

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

TRVI screens overvalued: fair value 34% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Trevi Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −34.3% · Below median
Profitability
Return on assets −22.1% · Below median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 12.74× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs TRVI
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs TRVI
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs TRVI
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs TRVI
argenx SE ARGX $971.55 $908.40 −7% vs TRVI
CSL Limited CSL A$201.68 A$181.40 −10% vs TRVI
Moderna, Inc MRNA $250.83 $158.70 −37% vs TRVI
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs TRVI
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs TRVI
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs TRVI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Trevi Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Trevi Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/TRVI

Frequently asked questions

Is Trevi Therapeutics Inc (TRVI) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $9.79 versus a price of $14.91, about 34% lower (overvalued).
What is the fair value of TRVI?
Our estimate for Trevi Therapeutics Inc is $9.79 (as of Nov 11, 2026), built from audited fundamentals. The current price: $14.91.
What is the quality score of TRVI?
Trevi Therapeutics Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Trevi Therapeutics Inc (TRVI)?
Our calculated price target is the estimate of $9.79 (as of Nov 11, 2026). Cautious scenario $7.34, optimistic scenario $12.23. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Trevi Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $9.79, about 34% lower versus a price of $14.91 (overvalued). Cautious scenario $7.34, optimistic scenario $12.23. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Trevi Therapeutics Inc (TRVI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Trevi Therapeutics Inc it is $9.79 per share (as of Nov 11, 2026), against a price of $14.91.
Is Trevi Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, TRVI trades above its calculated fair value: price $14.91, fair value $9.79, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TRVI?
No. The price is what the market pays today ($14.91); the fair value is what the company's own numbers justify ($9.79). For Trevi Therapeutics Inc the two are $5.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is Trevi Therapeutics Inc worth?
The market values Trevi Therapeutics Inc at about $2.3B (market capitalisation, as of Nov 11, 2026). Per share that is $14.91; our models calculate a fair value of $9.79 per share.
What do the bullish and bearish scenarios say about TRVI?
Our models span a range for Trevi Therapeutics Inc: cautious scenario $7.34, base $9.79, optimistic $12.23 per share (as of Nov 11, 2026, price $14.91). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Trevi Therapeutics Inc (TRVI)?
Balance-sheet figures for Trevi Therapeutics Inc (as of Nov 11, 2026): return on equity −19.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is TRVI from its 52-week high?
Trevi Therapeutics Inc trades at $14.91, about 24% below its 52-week high of $19.50 and 49% above the low of $9.99 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $9.79 is for.
Which stocks are comparable to Trevi Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Trevi Therapeutics Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $14.91, calculated fair value $9.79 (−34%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Trevi Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Trevi Therapeutics Inc (TRVI)?
The closing price on Nov 10, 2026 was $14.91. Our estimate is $9.79, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Trevi Therapeutics Inc right now?
The price sits above even our optimistic bull case ($12.23). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Trevi Therapeutics Inc

How large is the market capitalisation of Trevi Therapeutics Inc (TRVI)?
The market capitalisation of Trevi Therapeutics Inc is $2.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Trevi Therapeutics Inc (TRVI)?
Earnings per share at Trevi Therapeutics Inc are $−0.3700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Trevi Therapeutics Inc (TRVI)?
The return on equity (ROE) of Trevi Therapeutics Inc is −19.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Trevi Therapeutics Inc (TRVI)?
On an EBIT basis the return on assets of Trevi Therapeutics Inc is −43.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Trevi Therapeutics Inc (TRVI) generate?
The free cash flow of Trevi Therapeutics Inc is −$42.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Trevi Therapeutics Inc (TRVI) hold?
Trevi Therapeutics Inc holds more cash than debt, $18.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Trevi Therapeutics Inc in the live analysis

One click puts Trevi Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.